.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and total survival, resulting in FDA commendation and a new procedure choice for clients.